UBS Group’s Blonder Tongue Laboratories Inc BDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-9,435
| Closed | -$6K | – | 11628 |
|
|
2022
Q1 | $6K | Buy |
9,435
+3,071
| +48% | +$1.65K | ﹤0.01% | 9072 |
|
|
2021
Q4 | $4K | Buy |
6,364
+5,312
| +505% | +$5.01K | ﹤0.01% | 9625 |
|
|
2021
Q3 | $1K | Buy |
1,052
+82
| +8% | +$101 | ﹤0.01% | 9420 |
|
|
2021
Q2 | $1K | Buy |
+970
| New | +$1.19K | ﹤0.01% | 9297 |
|
|
2021
Q1 | – | Sell |
-591
| Closed | -$1K | – | 9758 |
|
|
2020
Q4 | $1K | Sell |
591
-13,027
| -96% | -$15.4K | ﹤0.01% | 8302 |
|
|
2020
Q3 | $11K | Buy |
13,618
+12,398
| +1,016% | +$10.1K | ﹤0.01% | 6808 |
|
|
2020
Q2 | $1K | Sell |
1,220
-5,436
| -82% | -$3.22K | ﹤0.01% | 7852 |
|
|
2020
Q1 | $4K | Buy |
6,656
+3,785
| +132% | +$2.9K | ﹤0.01% | 7439 |
|
|
2019
Q4 | $2K | Sell |
2,871
-4,050
| -59% | -$2.76K | ﹤0.01% | 7887 |
|
|
2019
Q3 | $5K | Buy |
6,921
+4,131
| +148% | +$3.38K | ﹤0.01% | 7508 |
|
|
2019
Q2 | $3K | Sell |
2,790
-8,327
| -75% | -$8.18K | ﹤0.01% | 7564 |
|
|
2019
Q1 | $12K | Buy |
11,117
+2,068
| +23% | +$2.34K | ﹤0.01% | 6711 |
|
|
2018
Q4 | $10K | Buy |
9,049
+9,000
| +18,367% | +$9.87K | ﹤0.01% | 7252 |
|
|
2018
Q3 | $0 | Sell |
49
-2,126
| -98% | -$2.75K | ﹤0.01% | 8395 |
|
|
2018
Q2 | $2K | Buy |
2,175
+2,172
| +72,400% | +$2.32K | ﹤0.01% | 7762 |
|
|
2018
Q1 | $0 | Sell |
3
-14,672
| -100% | -$9.42K | ﹤0.01% | 8310 |
|
|
2017
Q4 | $9K | Buy |
14,675
+5,352
| +57% | +$2.57K | ﹤0.01% | 7115 |
|
|
2017
Q3 | $4K | Buy |
9,323
+7,991
| +600% | +$4.16K | ﹤0.01% | 7340 |
|
|
2017
Q2 | $1K | Sell |
1,332
-1,575
| -54% | -$864 | ﹤0.01% | 7544 |
|
|
2017
Q1 | $2K | Sell |
2,907
-113,327
| -97% | -$76.5K | ﹤0.01% | 7326 |
|
|
2016
Q4 | $55K | Sell |
116,234
-61,641
| -35% | -$33.1K | ﹤0.01% | 5756 |
|
|
2016
Q3 | $109K | Buy |
177,875
+171,212
| +2,570% | +$98.9K | ﹤0.01% | 4940 |
|
|
2016
Q2 | $3K | Buy |
+6,663
| New | +$2.71K | ﹤0.01% | 7364 |
|
|
2015
Q3 | – | Sell |
-2,944
| Closed | -$2K | – | 8743 |
|
|
2015
Q2 | $2K | Buy |
+2,944
| New | +$2.32K | ﹤0.01% | 8235 |
|
|
2015
Q1 | – | Sell |
-10,018
| Closed | -$27K | – | 9580 |
|
|
2014
Q4 | $27K | Buy |
+10,018
| New | +$17.5K | ﹤0.01% | 7242 |
|
UBS Group's BDR Position: Q2 2022 in Review
UBS Group sold out of Blonder Tongue Laboratories Inc (BDR) in Q2 2022, closing a stake of 9,435 shares — an estimated $6K sold.
UBS Group first reported a position in BDR in Q4 2014 and held it in 25 quarters. The position peaked at $109K in Q3 2016. 0 funds tracked by Wall St. Rank hold BDR as of Q2 2022.
- UBS Group reported no remaining Blonder Tongue Laboratories Inc position as of Q2 2022 after selling out during the quarter.
- UBS Group sold 9,435 Blonder Tongue Laboratories Inc shares in Q2 2022, an estimated $6K.
- UBS Group first reported a position in Blonder Tongue Laboratories Inc in Q4 2014 and held it in 25 quarters.
- UBS Group's Blonder Tongue Laboratories Inc position peaked at $109K in Q3 2016.
- 0 funds tracked by Wall St. Rank held Blonder Tongue Laboratories Inc as of Q2 2022.
Based on UBS Group's 13F filing for Q2 2022, filed 10 Aug 2022.